Literature DB >> 10681614

Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related?

U Bader1, M Banyai, R Böni, G Burg, J Hafner.   

Abstract

Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. Vasculitis, cryoglobulinemia and pyoderma gangrenosum should be considered if typical clinical signs are present. We report on 3 patients with myeloproliferative disorders who developed HU-induced leg ulcers and review the literature. HU-induced leg ulcers share clinical features which can help to differentiate them from leg ulcers of other etiologies: occurrence under long-term treatment with HU at a dose of at least 1 g/day, localization in the malleolar region and spontaneous healing when HU is discontinued. We conclude that differentiation between disease-related and treatment-induced leg ulcers can be difficult and may not always be possible. In HU-induced leg ulcers, cessation of the drug typically leads to wound healing. Copyright (R) 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681614     DOI: 10.1159/000018315

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

1.  A Hydroxyurea-induced Leg Ulcer.

Authors:  Seon-Wook Hwang; Soon-Kwon Hong; Sang-Hyun Kim; Jong-Keun Seo; Deborah Lee; Ho-Suk Sung
Journal:  Ann Dermatol       Date:  2009-02-28       Impact factor: 1.444

2.  Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).

Authors:  Victoria K Shanmugam; Sean McNish; Nawar Shara; Katherine J Hubley; Bhaskar Kallakury; David M Dunning; Christopher E Attinger; John S Steinberg
Journal:  J Foot Ankle Surg       Date:  2013-08-14       Impact factor: 1.286

Review 3.  Successful Treatment of Chronic Lower Extremity Ulcers with Allogeneic Platelet-Rich Plasma and Artificial Dermis: A Case Report.

Authors:  Qiannan Zhao; Yuanyuan Ma; Yuquan Lu; Yuan Chai; Yuemin Zhou
Journal:  Adv Skin Wound Care       Date:  2019-12       Impact factor: 2.347

4.  Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.

Authors:  Nm Wiles; J Howard
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

5.  Healing of Chronic Wounds with Platelet-Derived Growth Factors from Single Donor Platelet-Rich Plasma following One Freeze-Thaw Cycle. A Cross-Sectional Study.

Authors:  Julia Vidán-Estévez; Sergio Sánchez-Herráez; Fernando Escalante-Barrigón; Jesús Seco-Calvo
Journal:  J Clin Med       Date:  2021-12-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.